LCAM
GILD icon

London & Capital Asset Management’s Gilead Sciences GILD Stock Holding History

London & Capital Asset Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$280K Sell
2,008
-971
-33% -$136K ﹤0.01% 201
2025
Q4 		$366K Buy
+2,979
New +$362K ﹤0.01% 195

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

London & Capital Asset Management's GILD Position: Q1 2026 in Review

London & Capital Asset Management reduced its Gilead Sciences (GILD) stake by 33% in Q1 2026, selling an estimated $136K and leaving 2,008 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #201.

London & Capital Asset Management first reported a position in GILD in Q4 2025 and has held it in 2 quarters since. The position peaked at $366K in Q4 2025. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • London & Capital Asset Management held 2,008 shares of Gilead Sciences worth $280K as of Q1 2026.
  • London & Capital Asset Management sold 971 Gilead Sciences shares in Q1 2026, an estimated $136K.
  • Gilead Sciences made up ﹤0.01% of London & Capital Asset Management's portfolio in Q1 2026, its #201 holding.
  • London & Capital Asset Management first reported a position in Gilead Sciences in Q4 2025 and has held it in 2 quarters since.
  • London & Capital Asset Management's Gilead Sciences position peaked at $366K in Q4 2025.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on London & Capital Asset Management's 13F filing for Q1 2026, filed 15 May 2026.